Mon, September 27, 2010
[ Mon, Sep 27th 2010 ] - Market Wire
Wellstar Announces New Website
Sun, September 26, 2010
Sat, September 25, 2010
Fri, September 24, 2010
Thu, September 23, 2010
Wed, September 22, 2010
Tue, September 21, 2010
Mon, September 20, 2010
Fri, September 17, 2010
Thu, September 16, 2010
Wed, September 15, 2010
[ Wed, Sep 15th 2010 ] - Market Wire
Qtrax Beta Available in India
Tue, September 14, 2010
Mon, September 13, 2010
Sun, September 12, 2010
Fri, September 10, 2010
Thu, September 9, 2010
Wed, September 8, 2010
Tue, September 7, 2010
Sat, September 4, 2010
[ Sat, Sep 04th 2010 ] - Market Wire
Transdel Pharmaceuticals
Fri, September 3, 2010
[ Fri, Sep 03rd 2010 ] - Market Wire
Transdel Pharmaceuticals

Law Office of Jonathan M. Stein, P.L. Investigates Possible Breaches of Fiduciary Duty by the Officers and Directors of Acura P


//health-fitness.news-articles.net/content/2010/ .. ty-by-the-officers-and-directors-of-acura-p.html
Published in Health and Fitness on Tuesday, September 14th 2010 at 12:45 GMT by Market Wire   Print publication without navigation


BOCA RATON, Fla.--([ BUSINESS WIRE ])--The Law Office of Jonathan M. Stein, P.L. is investigating the officers and directors of Acura Pharmaceuticals, Inc. ("Acura" or the "Company") (Nasdaq:ACUR) for possible breaches of fiduciary duty and other violations of state and federal law. On September 10, 2010, a class action lawsuit was filed in the U.S. District Court for the Northern District of Illinois alleging that certain officers and directors of the Company violated the Securities Exchange Act of 1934 by concealing material adverse facts about the Companya™s product Acurox, a drug containing oxycodone with a niacin additive.

The investigation involves whether the officers and directors of Acura breached their fiduciary duties to Acura stockholders by failing to disclose the truth about the effectiveness of Acurox and its proprietary aAversion Technologya that supposedly provides abuse deterrent qualities to orally-administered drugs, such as Acurox. Specifically, on April 20, 2010, the FDA indicated that Acura's Aversion Technology was nowhere near effective enough to warrant approval, that the Company's clinical data was defective, that its clinical studies were not properly designed, that the Company had wholly ignored specific directives from FDA over the past four years as to specific clinical trials and evidence Acura had to demonstrate, and that no evidence had ever been presented to the FDA that the niacin additive discouraged abusers from abusing oxycodone.

If you currently own stock in Acura and wish to discuss your rights as a shareholder, or if you have information regarding the above investigation, please contact Jonathan M. Stein, Esq. either via email at [ jstein@jonathansteinlaw.com ] or by telephone at (561) 961-2244.

The Law Office of Jonathan M. Stein, P.L.represents shareholders and consumers in complex litigation, including class action and derivative litigation. More information about the firm is available through its website, [ www.jonathansteinlaw.com ], and upon request from the firm. Jonathan M. Stein is the attorney responsible for the content of this release.


Publication Contributing Sources